Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

13.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Guided Prioritization and Synthesis of New Ligands for GPR17 Receptor.

ACS omega·2026
Same author

Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Selection of Functional Glycoforms in Anti-SARS-CoV-2 Human IgG1 Monoclonal Antibodies by FcγRIIIa Affinity Chromatography and Mass Spectrometry.

Journal of medicinal chemistry·2026
Same author

The cytokine signature in multiple sclerosis: a study during the SARS-CoV-2 pandemic.

Frontiers in immunology·2026
Same author

EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients.

Multiple sclerosis and related disorders·2026
Same author

The cerebellar cognitive affective syndrome scale in early multiple sclerosis.

Journal of neurology·2026

Related Experiment Video

Updated: May 6, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K

Polyclonal Antibody Therapeutics: Analytical Innovations and Regulatory Perspectives for Addressing Heterogeneity

Sunil Kumar1, Aurora Tini1, Sara Tengattini1

  • 1Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.

Analytical Chemistry
|February 19, 2026
PubMed
Summary

Polyclonal antibodies (pAbs) offer advantages over monoclonal antibodies (mAbs) but face characterization challenges. New high-resolution analytical methods are enabling better quality control for pAb therapeutics, improving their clinical development.

More Related Videos

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

17.3K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Experiment Videos

Last Updated: May 6, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

16.9K
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

17.3K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Area of Science:

  • Immunology and Biotechnology
  • Analytical Chemistry
  • Pharmaceutical Sciences

Background:

  • Polyclonal antibodies (pAbs) are vital for adaptive immunity and used therapeutically as intravenous immunoglobulins (IVIg).
  • pAbs offer production advantages over monoclonal antibodies (mAbs) but their heterogeneity poses analytical and regulatory hurdles.
  • Current analytical methods lack the resolution to fully characterize pAb critical quality attributes (CQAs).

Purpose of the Study:

  • To highlight advances in high-resolution analytical technologies for pAb characterization.
  • To discuss the importance of assessing pAb CQAs for therapeutic development.
  • To explore the evolving regulatory landscape for pAb-based therapeutics.

Main Methods:

  • Review of recent advancements in chromatographic and mass spectrometric techniques.
  • Focus on analytical strategies for assessing pAb structural integrity, molecular size, subclass composition, and polyclonality.
  • Examination of regulatory frameworks and the need for standardized analytical criteria.

Main Results:

  • High-resolution analytical technologies enable in-depth characterization of pAb CQAs.
  • These methods facilitate the assessment of crucial parameters for ensuring product quality and consistency.
  • Evolving regulatory frameworks support the development of standardized analytical criteria for pAbs.

Conclusions:

  • Integrating advanced analytical capabilities with regulatory expectations can enhance pAb therapeutic development.
  • Improved characterization will enable pAbs to more effectively complement mAbs in clinical practice.
  • Standardized analytical approaches are key to ensuring the safety, efficacy, and consistency of pAb therapeutics.